A FORMULATION DISPLAYING AN ANTI-CARCINOGENIC EFFECT WITH HIF-1 ALPHA SUPPRESSION
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Hif-1 Alpha iNOS

description: <strong>Field of Invention</strong> The present invention herewith discloses a formulation developed to display an anti-carcinogenic effect by hif-1 alpha suppression. <strong>Background of the Related Technology</strong> At present in molecular biology, it is known that the transcription factor is a protein that can bind to a certain sequence on the DNA, to regulate the transcription of genes. These are also called sequence specific DNA binding protein. Transcription factors, alone or together with other proteins found in the complex, either (as an activator) facilitate or (as a repressor) prevent transcription of a gene by RNA polymerase. Transcription factors may also exist at the end of signal sequences, generated by environmental stimuli. Examples to these are heat shock factor (HSF) that enables one to stay alive at high temperatures, hypoxia inducible factor (HIF) that supports life in an environment with low level of oxygen and sterol regulatory element binding protein (SREBP) that regulates the level of lipids inside the cell. In state of art technology, invention no “PCT/US00/22610", with title “Chlorite solutions for treating cancer and other diseases" and under classification number “A61K 33/40" discloses the methods of using a stabilized chlorite matrix to modulate immune responses and treat cancer. The stabilized chlorite matrix, when administered to a mammal in need thereof, can activate immune cells in a manner similar to interferon gamma, but does not affect the production of inflammatory and shock related cytokines like tumor necrosis alpha. The stabilized chlorite matrix also up regulates the expression of the DCC protein in macrophages; where the referred DCC protein is a protein whose expression is related to neoplastic transformation. Thus the stabilized chlorite matrix therefore is useful as an immunomodulatory agent and in treating cancer Again invention no “WO 1998/046642", with title “Modified TNF alpha molecules" and under classification number “C07K 14/525" discloses a modified TNF alpha molecule, which is capable of raising neutralizing antibodies towards wild-type human TNFα, following administration of said modified TNFα molecule to a human host. The modified human TNFα molecules or DNA encoding them, may be formulated as vaccines against TNFα, optionally with pharmaceutically acceptable adjuvants, for the prevention or treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, cancer, disseminated sclerosis, diabetes, psoriasis, osteoporosis or asthma. Human body fluids, may be tested for the presence of TNFα by contact with a composition containing the modified TNFα. Again invention no “EP2282772B1", with title “Compositions and methods to enhance the immune system" and under classification number “A61K 39/275" relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. The referred invention also relates to a composition comprising (i) a therapeutic composition that can trigger a host's immune effector cells against an aberrant cell like a therapeutic antibody and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended to display an anti-carcinogenic effect by hif-1 alpha suppression. <strong>Objective of the Invention</strong> To overcome the disadvantages experienced in state of art technology; One objective of the invention is to suppress hif-1(hypoxia inducible factor type 1) expression. One other objective of the invention is to provide effective systemic cardio-vascular and micro-vascular support One other objective of the invention is to display iNOS suppressing capability. The present invention which is aimed to achieve the above-mentioned advantages, is intended to display an anti-carcinogenic effect by hif-1 alpha suppression and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention herewith discloses a formulation developed to display an anti-carcinogenic effect by hif-1 alpha suppression. Referred formulation suppresses hif-1(hypoxia inducible factor type 1) expression, provides effective systemic cardio-vascular and micro-vascular support, displays iNOS suppressing capability. The formulation of the invention presented herewith contains; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol . The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 1-99% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 99-1% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time discloses using the above-referred formulation to display an anti-carcinogenic effect by hif-1 alpha suppression and manufacturing it for such purpose. <strong>CLAIMS</strong> A formulation intended to display an anti-carcinogenic effect by hif-1 alpha suppression, which consists of combining the components selected from the group; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol in a single form or in combinations thereof. The formulation of Claim 1 which is characterized by containing 1-99% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione by weight. The formulation of Claim 1 which is characterized by containing 99-1% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(trihydroxymethyl)oxane-3,5,-diol from any one as given in Claims 2-3 in manufacturing the formulation intended to display an anti-carcinogenic effect by hif-1 alpha suppression. <strong>SUMMARY</strong> <strong>A FORMULATION DISPLAYING AN ANTI-CARCINOGENIC EFFECT WITH HIF-1 ALPHA SUPPRESSION</strong> The present invention herewith discloses a formulation developed to display an anti-carcinogenic effect by hif-1 alpha suppression. Referred formulation suppresses hif-1(hypoxia inducible factor type 1) expression, provides effective systemic cardio-vascular and micro-vascular support, displays iNOS suppressing capability. There are no illustrations.